Article info

Download PDFPDF

Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series
Free

Authors

  1. Correspondence to Javier Narváez, Department of Rheumatology, Hospital Universitario de BellvitgeFeixa Llarga, Barcelona 08907, Spain; fjnarvaez{at}bellvitgehospital.cat
View Full Text

Citation

Narváez J, LLuch J, Alegre Sancho JJ, et al
Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series

Publication history

  • Received September 16, 2018
  • Accepted September 20, 2018
  • First published October 23, 2018.
Online issue publication 
October 15, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.